New Phase 3 trial: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease — Hoffmann-La Roche
Why now
Thesis: Roche enters obesity race with petrelintide trial
Catalyst to watch: Enrollment and interim efficacy data
Main risk: Competitive or efficacy setbacks possible
Why it matters
A large obesity/cardiovascular Phase 3 for petrelintide positions Roche in the competitive weight-loss market.
Details
Sponsor: Hoffmann-La Roche; Status: Not Yet Recruiting; Conditions: Obesity or Overweight, Cardiovascular Disease; Interventions: Petrelintide, Placebo; Enrollment: 2500 (estimated); First posted: 2026-09-28; NCT: NCT07843472
Sources
- clinicaltrials · 2026-09-28 12:00 UTC
- clinicaltrials · 2026-09-28 12:00 UTC
- clinicaltrials · 2026-09-28 12:00 UTC